Last reviewed · How we verify
Intravenous Treprostinil
Intravenous Treprostinil, marketed by United Therapeutics, is a prostacyclin analog used primarily for the treatment of pulmonary arterial hypertension (PAH). The drug's key strength lies in its well-established market position, supported by a key composition patent that expires in 2028. The primary risk to the drug's market position is the potential increase in competition as the patent expiration approaches.
At a glance
| Generic name | Intravenous Treprostinil |
|---|---|
| Also known as | Remodulin |
| Sponsor | United Therapeutics |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study (NA)
- Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients (PHASE4)
- Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn (PHASE2)
- TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) (PHASE4)
- Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH (PHASE4)
- Rapid Switch From Flolan to Remodulin in the Outpatient Clinic (PHASE4)
- EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension (PHASE4)
- Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Treprostinil CI brief — competitive landscape report
- Intravenous Treprostinil updates RSS · CI watch RSS
- United Therapeutics portfolio CI